News
New research found GLP-1 users in the real world lose less weight compared to participants in clinical trials.
Telehealth firm 9amHealth has partnered with billionaire entrepreneur Mark Cuban's Cost Plus Drug Company to offer U.S.
Researchers from George Washington University have uncovered promising evidence in an animal study that shows setmelanotide, ...
Eli Lilly's stock price has over-corrected following a downgrade in its outlook following the adjustment for acquisition ...
Many focus on what weight-loss drugs take away: pounds. But they also offer patients something new: a sense of agency.
1don MSN
Patients with obesity can now get Zepbound’s strongest doses for a flat rate through Lilly’s self-pay pharmacy. Eli Lilly ...
Eli Lilly will ship the two highest doses of its popular weight-loss drug Zepbound to cash-paying customers on its website ...
Despite the jump in the number of teens being prescribed Wegovy, it still represents only a small fraction of kids who are living with obesity. Approximately one in 5 children and teens in the U.S.
Eli Lilly is unleashing self-pay discounts across the entirety of its obesity portfolio with new price cuts for higher doses ...
While some compounding pharmacies have stopped making alternatives to Wegovy and Zepbound since shortages were declared over, ...
Eli Lilly will start selling the two highest doses of its popular weight-loss drug Zepbound directly to customers online in ...
Eli Lilly expands Zepbound access with flat-rate pricing and new vial options, supporting wider obesity treatment access ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results